Systemic Lupus Erythematosus (SLE)Early Phase 1NCT07339332
A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell Injection in Moderate to Severe Refractory Systemic Lupus Erythematosus
A Early Phase 1 study testing CAR-T Therapy in people with Systemic Lupus Erythematosus (SLE), run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology at 1 site in China.
Trial summary
This study is a single arm, open, exploratory dose escalation clinical study to evaluate the safety, efficacy, and cellular metabolic dynamics of ct1195e cells in patients with SLE. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Systemic Lupus Erythematosus (SLE)
- What is being tested?
- CAR-T Therapy
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 12 participants
- Where
- 1 siteChina
- Study dates
- 16 Jan 2026to 31 Dec 2027
- Phase
- Early Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Voluntary signing of Informed Consent Form (ICF): I fully understand and am informed of this study, and I have signed the Informed Consent Form, expressing my willingness to follow and complete all research procedures;
- When signing the ICF, the age should be between 18 and 65 years old (inclusive), with no gender restrictions;
- No systemic active infection (such as infectious pneumonia, tuberculosis) within 2 weeks before screening;
- Females with fertility (defined as all females who are physiologically capable of becoming pregnant) must agree to use highly effective contraception from at least 28 days before the start of self-cleaning to 1 year after CT1195E infusion, and absolutely prohibit egg donation within 1 year after receiving study treatment during the study period. Their male partners with fertility must agree to use effective barrier contraception from the start of self-cleaning to 1 year after CT1195E infusion, and should not donate semen or sperm during the entire study period;
- Females with fertility must have a negative serum beta-human chorionic gonadotropin (β-hCG) test result at screening and within 48 hours prior to the initiation of chemotherapy.
- Meet the EULAR/ACR 2019 classification criteria for SLE, with a disease history of ≥6 months;
Show all 18Show fewer
- Prior to screening, patients must have received treatment with glucocorticoids combined with immunosuppressants (including cyclophosphamide, mycophenolate mofetil, tacrolimus, methotrexate, cyclosporine, leflunomide) and/or biologics for ≥3 months, with a stable dosage for ≥2 weeks, and the disease must still be in an active state. During screening, oral steroids must meet the following requirements:
- If treated with hormone therapy alone, prednisone (or equivalent medication) should be ≥7.5 mg/day; When used in combination with immunosuppressants and/or biologics, there is no minimum daily dosage requirement for steroids;
- During screening, positive for antinuclear antibody, and/or positive for anti-ds-DNA antibody, and/or positive for anti-Smith antibody;
- During the screening period, patients with a SLEDAI-2K score of ≥7, or those with concurrent significant organ dysfunction, such as severe immune-mediated thrombocytopenia, lupus nephritis (histologically diagnosed as active nephritis type III or IV with or without type V);
- During screening, involvement of active organs (including kidneys, heart and lungs, musculoskeletal system, blood system, blood vessels, etc.; involvement of skin and mucous membranes alone is not included) is present;
- Adequate organ function:
- Renal function: defined as creatinine clearance rate (Cockcroft-Gault) calculated without hydration assistance ≥ 50 mL/min;
- Bone marrow function: defined as absolute neutrophil count (ANC) ≥1.0×10^9/L and hemoglobin (Hb) ≥60 g/L. During the 7 days prior to screening for inclusion and exclusion criteria, blood transfusions and growth factors must not be used to meet these requirements;
- Liver function: defined as alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels ≤2× upper limit of normal (ULN), and total bilirubin levels ≤2× upper limit of normal (ULN)
- Coagulation function: defined as an international normalized ratio (INR) or activated partial thromboplastin time (APTT) ≤1.5×ULN;
- Lung function: When exposed to indoor air, the blood oxygen saturation (SpO2) is ≥92% (measured by a pulse oximeter);
- Cardiac function: defined as having a left ventricular ejection fraction (LVEF) of ≥50% as assessed by echocardiography (ECHO) within the 8 weeks prior to screening.
Who cannot join
- Those who have suffered from severe lupus nephritis within the previous 2 months and require hemodialysis, or have received prednisone ≥100 mg/d or equivalent hormone treatment for ≥14 days;
- Those who have undergone plasma exchange, plasma separation, hemodialysis within the previous 30 days, or those who have suffered from lupus crisis within the previous 30 days;
- Screen for individuals with a history of ≥ Grade 2 bleeding within the previous 30 days or those requiring long-term anticoagulant therapy;
- History of any of the following cardiovascular diseases within 30 days prior to screening: heart failure of NYHA class III or IV, myocardial infarction, unstable angina, uncontrolled or symptomatic atrial arrhythmias, any ventricular arrhythmias, or other clinically significant heart diseases;
- Before screening, there were manifestations of the central nervous system caused by lupus, including but not limited to lupus headache, seizures, cognitive impairment, impaired intellectual function, and visual impairment;
- Individuals with central nervous system diseases prior to screening include, but are not limited to: cerebrovascular accident, encephalitis, epilepsy, convulsion/seizure, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disease, central nervous system vasculitis, cognitive dysfunction, brain organic syndrome, or psychosis;
Show all 23Show fewer
- Screen for the absence of systemic active infections within the previous 2 weeks, including but not limited to active tuberculosis;
- Previous exposure to CAR-T cell therapy or other gene-modified T cell therapies, or a history of major organ transplantation (such as heart, lung, kidney, liver) or hematopoietic stem cell/bone marrow transplantation;
- Allergic or intolerant to diuretics, tocilizumab, or experiencing life-threatening allergic reactions, hypersensitivity reactions, or intolerance to CT1195E formulation or its excipients (including dimethyl sulfoxide (DMSO)), or having a history of other severe allergies such as anaphylactic shock;
- Screen for individuals who have used targeted B-cell drugs such as rituximab within the previous 3 months;
- Exclusion criteria: Subjects who have used other biologics such as TACI-Ig and Benlysta within the previous 12 weeks;
- Within 2 weeks prior to the infusion of CT1195E, the use of prednisone (or equivalent drugs) at a dosage of ≥10 mg/day is allowed. Physiological substitutes, topical, and inhaled steroids are also permitted;
- Received T-cell-affecting immunosuppressants (mycophenolate mofetil, methotrexate, cyclosporine, azathioprine, leflunomide, tacrolimus) within 2 weeks before infusion of CT1195E;
- Have received JAK inhibitors (such as tofacitinib, baricitinib, ruxolitinib, etc.) within 2 weeks before the infusion of CT1195E;
- Have received attenuated live vaccine, inactivated vaccine, or RNA vaccine within one month before screening;
- Suffered from malignant tumor within 2 years before signing the ICF. The following conditions are excluded: non-melanoma skin cancer that has undergone radical treatment, localized prostate cancer, biopsy-confirmed cervical carcinoma in situ or squamous intraepithelial lesion detected by cervical smear, and completely resected breast carcinoma in situ;
- The participant has undergone major surgery within 4 weeks prior to signing the informed consent form, or plans to undergo major surgery during the study period, and the investigator believes that this would pose an unacceptable risk to the study participant;
- During screening, there is evidence of HIV, syphilis infection, active hepatitis B virus infection (HBsAg positive and HBV-DNA above the detection limit), or active hepatitis C virus infection (both HCV antibody and HCV-RNA positive);
- Those who participated in other clinical studies within the previous three months or are still within the five half-lives after the last dose;
- Concurrent major chronic diseases that are not under control and that the investigator believes may increase the risk to study participants;
- Subjects with a history or evidence of suicidal thoughts within the previous 6 months, or any suicidal behavior within the previous 12 months, are considered by the researchers to have a significant risk of suicide;
- Pregnant or lactating women;
- The researcher judges that the study participant has poor compliance, is unable or unwilling to adhere to the requirements of the study protocol, or has other reasons that make them unsuitable for participating in this clinical study.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Wuhan Union Hospita
Wuhan, Hubei, 430000
Qiubai Li, Professor 85726808 Ext. 027, qiubaili@hust.edu.cn
About this study
This study is a single arm, open, exploratory dose escalation clinical study to evaluate the safety, efficacy, and cellular metabolic dynamics of ct1195e cells in patients with SLE.
Read the detailed description
The study was divided into dose increasing stage and dose expanding stage.dose escalation phaseThree dose levels are tentatively determined for dose escalation: 3.0 × 108, 4.5 × 108 and 6.0 × 108 car-cd19/CD20+T cells. It is estimated that the target toxicity probability of the maximum tolerated dose is 30%, and about 12 participants are planned to be enrolled, and the number of enrolled patients in each dose group is subject to the actual situation. During the test, the researchers and partners will jointly negotiate whether to increase or decrease the dose, whether to increase to the set maximum dose group or produce the maximum available cell volume, and whether to increase the exploration of new dose level within the explored dose range (allowed to be conducted when the dose is increased or decreased) according to the participants' cell metabolism characteristics, safety, tolerance and preliminary effectiveness data, so as to determine the possible recommended therapeutic dose (RD).The DLT observation period is 28 days after the first infusion. If the treatment needs to be withdrawn before 28 days after the infusion due to disease progression or other reasons, no obvious car-t cell expansion is detected or car-t treatment is invalid, and the DLT related AE events determined by the researcher may not be related to the product, the DLT observation period can be completed before. During each dose increase, if there is a safety risk that needs to be discussed, the researchers and partners can make a dose increase/stability/decrease decision according to the safety and tolerance of participants and the metabolic kinetics of ct1192 cells. In the same dose group, the first participant had no significant safety risk 14 days after the completion of cell infusion, and subsequent participants could only carry out cell infusion.dose expansion phaseOne or more dose groups may be selected for dose expansion according to the results of the dose increasing stage to further explore the efficacy and safety in SLE patients. Each dose group and each queue plan to include up to 9 cases, and the specific number of patients in the group is subject to the actual number. DLT will not be observed in the dose expansion phase, and other research processes are the same as the dose increment phase. Researchers and collaborators will continue to monitor the safety data of the whole dose expansion phase and make decisions on admission and exit when necessary.
- Conditions
- Systemic Lupus Erythematosus (SLE)
- Being tested
- CAR-T Therapy
- Medical subject headings
- Lupus Erythematosus, Systemic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CAR-T TherapyOther
CT1195E cells infusion
| Study group | Role | What they receive |
|---|---|---|
| CT1195E CAR-T cells Injection | Experimental | CT1195E cells infusion Receives: Other: CAR-T Therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
severity of dose limiting toxicity (DLT)
Measured: Within 28 days after infusion
Incidence of dose limiting toxicity (DLT)
Measured: Within 28 days after infusion
Evaluate the maximum tolerable dose (MTD) and/or dose range of ct1195E
Ct1195E MTD and/or dose range
Measured: After medication to day 28
severity of adverse events (AES)
Measured: Within 180 days after infusion
Incidence of adverse events (AES)
Measured: Within 180 days after infusion
Secondary outcomes (14)
Proportion of participants with SLE responder index (sri-4)
Preliminary evaluation of the efficacy of ct1195E in the treatment of moderate to severe refractory SLE.Proportion of participants who reached SLE responder index (sri-4) at 6 months and other time points (1, 2,3, 9 and 12 months after medication)
Measured: 1, 2,3, 6, 9 and 12 months after drug use
Proportion of participants with low lupus disease activity status (lldas)
To evaluate the efficacy of ct1195E in the treatment of moderate to severe refractory SLE. The proportion of participants who reached lupus low disease activity status (lldas) at 6 months and other time points (1, 2, 3, 9 and 12 months after medication).
Measured: 1, 2,3, 6, 9 and 12 months after drug use
Proportion of participants achieving disease remission (doris)
To evaluate the efficacy of ct1195E in the treatment of moderate to severe refractory SLE. The proportion of participants who achieved disease remission (doris) at 6 months and other time points ((1, 2, 3, 9 and 12 months after medication).
Measured: 1, 2, 3, 6, 9 and 12 months after drug use
Changes of SLE disease activity index (sledai-2k) score from baseline after medication
The score range of the Health Assessment Questionnaire Disability Index (HAQ-DI) is usually 0 to 3, where 0 represents no disability or intact function, and 3 represents severe disability or complete loss of function. The higher the score, the worse the functional status of the patient, that is, the higher the degree of disability; Conversely, the lower the score, the better the function.
Measured: 1,2,3,6,9 and 12 months after drug use
After treatment, the SLE disease activity index (Selena - SLEDAI) score changed from baseline
The minimum value of selena-sledai score is 0 points, and the maximum value can reach 105 points theoretically, but in actual clinical practice, 10 to 15 points usually indicate the presence of disease activity. Higher scores indicate higher disease activity rather than better outcomes. The score is used to quantify the activity of systemic lupus erythematosus (SLE). An increase in the score reflects a more active condition, which requires active clinical intervention; Conversely, a reduced score indicates good disease control.
Measured: 1, 2, 3, 6, 9 and 12 months after drug use
After treatment, the index of lupus erythematosus assessment group (bilag-2004) changed from baseline
The minimum value of the British Isle lupus rating group index (bilag-2004) is 0 and the maximum value is 100. The higher the score, the higher the disease activity, that is, the more serious the disease.
Measured: 1, 2, 3, 9 and 12 months after drug use
The SLE activity score (sle-das) changed from baseline after treatment
The minimum value of sle-das score (systemic lupus erythematosus disease activity score) is 0, and the maximum value is usually 100. This score quantifies the disease activity by accumulating the scores of clinical and laboratory indicators. The higher the score, the stronger the disease activity and the more serious the disease.
Measured: 1, 2, 3, 9 and 12 months after drug use
Changes in clinicians' overall judgment (PGA) score from baseline after medication
In systemic lupus erythematosus (SLE), the minimum value of the doctors' global assessment (PGA) score is 0, and the maximum value is 3, where 0 indicates no disease activity and 3 indicates the most serious disease activity. The higher the score, the higher the disease activity, that is, the worse the result; Conversely, the lower the score, the lower the disease activity, and the better the result.
Measured: 1, 2, 3, 9 and 12 months after drug use
Proportion of patients without other SLE therapy after medication
Measured: 1, 2, 3, 9 and 12 months after drug use
Changes in immunoglobulin (IgG, IgM, IgA) levels during medication
Measured: 1, 2, 3, 9 and 12 months after drug use
The change value of post medication Health Assessment Questionnaire Disability Index (HAQ-DI) from baseline
The minimum possible score of patients with systemic lupus erythematosus (SLE) using the Health Assessment Questionnaire Disability Index (HAQ-DI) is 0, and the maximum possible score is 3; The higher the score, the more severe the dysfunction of the patient, that is, the worse the outcome.
Measured: 1, 2, 3, 9 and 12 months after drug use
duration of ct1195E gene in blood
Objective to evaluate the cell kinetics of ct1195E in SLE participants, and to observe the level and duration of ct1195E gene copy number in blood.
Measured: Within 1 year after CAR-T cell infusion
Copy numbe of ct1195E gene in blood
Objective to evaluate the cell kinetics of ct1195E in SLE participants, and to observe the level and duration of ct1195E gene copy number in blood.
Measured: Within 1 year after CAR-T cell infusion
Changes of B cell functional subsets (initial B cells, memory B cells, plasma cells) after ct1195E infusion
Evaluate the efficacy (PD) characteristics of CT1195E in SLE participants. Changes in the levels of B cell functional subgroups (initial B cells, memory B cells, plasma cells) after CT1195E infusion.
Measured: Within 1 year after CAR-T cell infusion
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jan 2026
- Study start16 Jan 2026 (estimated)
- Primary completion30 Jun 2027 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Systemic Lupus Erythematosus (SLE)Studies of the same condition, open and under way.
- More trials run by Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Early Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 12 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Collaborators
- CARsgen Therapeutics Co., Ltd.
- Responsible party
- Principal investigator, Qiubai Li, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07339332
- Sponsor's protocol ID
- CT1195E-CG11009
- Status last verified
- Nov 2025
- First submitted
- 18 Nov 2025
- Last updated
- 14 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell Injection in Moderate to Severe Refractory Systemic Lupus Erythematosus
- ClinicalTrials.gov ID
- NCT07339332
- Acronym / sponsor ID
- CT1195E-CG11009
- Conditions
- Systemic Lupus Erythematosus (SLE)
- Phase
- Early Phase 1
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 12 participants (estimated)
- Lead sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyUniversity, hospital or other
- Collaborators
- CARsgen Therapeutics Co., Ltd.
- Study start
- 16 Jan 2026 (estimated)
- Primary completion
- 30 Jun 2027 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 14 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a single arm, open, exploratory dose escalation clinical study to evaluate the safety, efficacy, and cellular metabolic dynamics of ct1195e cells in patients with SLE.
Detailed description
The study was divided into dose increasing stage and dose expanding stage.dose escalation phaseThree dose levels are tentatively determined for dose escalation: 3.0 × 108, 4.5 × 108 and 6.0 × 108 car-cd19/CD20+T cells. It is estimated that the target toxicity probability of the maximum tolerated dose is 30%, and about 12 participants are planned to be enrolled, and the number of enrolled patients in each dose group is subject to the actual situation. During the test, the researchers and partners will jointly negotiate whether to increase or decrease the dose, whether to increase to the set maximum dose group or produce the maximum available cell volume, and whether to increase the exploration of new dose level within the explored dose range (allowed to be conducted when the dose is increased or decreased) according to the participants' cell metabolism characteristics, safety, tolerance and preliminary effectiveness data, so as to determine the possible recommended therapeutic dose (RD).The DLT observation period is 28 days after the first infusion. If the treatment needs to be withdrawn before 28 days after the infusion due to disease progression or other reasons, no obvious car-t cell expansion is detected or car-t treatment is invalid, and the DLT related AE events determined by the researcher may not be related to the product, the DLT observation period can be completed before. During each dose increase, if there is a safety risk that needs to be discussed, the researchers and partners can make a dose increase/stability/decrease decision according to the safety and tolerance of participants and the metabolic kinetics of ct1192 cells. In the same dose group, the first participant had no significant safety risk 14 days after the completion of cell infusion, and subsequent participants could only carry out cell infusion.dose expansion phaseOne or more dose groups may be selected for dose expansion according to the results of the dose increasing stage to further explore the efficacy and safety in SLE patients. Each dose group and each queue plan to include up to 9 cases, and the specific number of patients in the group is subject to the actual number. DLT will not be observed in the dose expansion phase, and other research processes are the same as the dose increment phase. Researchers and collaborators will continue to monitor the safety data of the whole dose expansion phase and make decisions on admission and exit when necessary.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| CT1195E CAR-T cells Injection | Experimental | Other: CAR-T TherapyCT1195E cells infusion |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (18 listed)
- Voluntary signing of Informed Consent Form (ICF): I fully understand and am informed of this study, and I have signed the Informed Consent Form, expressing my willingness to follow and complete all research procedures;
- When signing the ICF, the age should be between 18 and 65 years old (inclusive), with no gender restrictions;
- No systemic active infection (such as infectious pneumonia, tuberculosis) within 2 weeks before screening;
- Females with fertility (defined as all females who are physiologically capable of becoming pregnant) must agree to use highly effective contraception from at least 28 days before the start of self-cleaning to 1 year after CT1195E infusion, and absolutely prohibit egg donation within 1 year after receiving study treatment during the study period. Their male partners with fertility must agree to use effective barrier contraception from the start of self-cleaning to 1 year after CT1195E infusion, and should not donate semen or sperm during the entire study period;
- Females with fertility must have a negative serum beta-human chorionic gonadotropin (β-hCG) test result at screening and within 48 hours prior to the initiation of chemotherapy.
Key exclusion criteria (23 listed)
- Those who have suffered from severe lupus nephritis within the previous 2 months and require hemodialysis, or have received prednisone ≥100 mg/d or equivalent hormone treatment for ≥14 days;
- Those who have undergone plasma exchange, plasma separation, hemodialysis within the previous 30 days, or those who have suffered from lupus crisis within the previous 30 days;
- Screen for individuals with a history of ≥ Grade 2 bleeding within the previous 30 days or those requiring long-term anticoagulant therapy;
- History of any of the following cardiovascular diseases within 30 days prior to screening: heart failure of NYHA class III or IV, myocardial infarction, unstable angina, uncontrolled or symptomatic atrial arrhythmias, any ventricular arrhythmias, or other clinically significant heart diseases;
- Before screening, there were manifestations of the central nervous system caused by lupus, including but not limited to lupus headache, seizures, cognitive impairment, impaired intellectual function, and visual impairment;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CAR-T TherapyCT1195E cells infusion | Other | CT1195E CAR-T cells Injection |
Primary outcome
severity of dose limiting toxicity (DLT)
Time frame: Within 28 days after infusion
Incidence of dose limiting toxicity (DLT)
Time frame: Within 28 days after infusion
Evaluate the maximum tolerable dose (MTD) and/or dose range of ct1195E
Time frame: After medication to day 28
Ct1195E MTD and/or dose range
severity of adverse events (AES)
Time frame: Within 180 days after infusion
Incidence of adverse events (AES)
Time frame: Within 180 days after infusion
14 secondary outcomes
Proportion of participants with SLE responder index (sri-4)
Time frame: 1, 2,3, 6, 9 and 12 months after drug use
Proportion of participants with low lupus disease activity status (lldas)
Time frame: 1, 2,3, 6, 9 and 12 months after drug use
Proportion of participants achieving disease remission (doris)
Time frame: 1, 2, 3, 6, 9 and 12 months after drug use
Changes of SLE disease activity index (sledai-2k) score from baseline after medication
Time frame: 1,2,3,6,9 and 12 months after drug use
After treatment, the SLE disease activity index (Selena - SLEDAI) score changed from baseline
Time frame: 1, 2, 3, 6, 9 and 12 months after drug use
After treatment, the index of lupus erythematosus assessment group (bilag-2004) changed from baseline
Time frame: 1, 2, 3, 9 and 12 months after drug use
The SLE activity score (sle-das) changed from baseline after treatment
Time frame: 1, 2, 3, 9 and 12 months after drug use
Changes in clinicians' overall judgment (PGA) score from baseline after medication
Time frame: 1, 2, 3, 9 and 12 months after drug use
Proportion of patients without other SLE therapy after medication
Time frame: 1, 2, 3, 9 and 12 months after drug use
Changes in immunoglobulin (IgG, IgM, IgA) levels during medication
Time frame: 1, 2, 3, 9 and 12 months after drug use
The change value of post medication Health Assessment Questionnaire Disability Index (HAQ-DI) from baseline
Time frame: 1, 2, 3, 9 and 12 months after drug use
duration of ct1195E gene in blood
Time frame: Within 1 year after CAR-T cell infusion
Copy numbe of ct1195E gene in blood
Time frame: Within 1 year after CAR-T cell infusion
Changes of B cell functional subsets (initial B cells, memory B cells, plasma cells) after ct1195E infusion
Time frame: Within 1 year after CAR-T cell infusion
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jan 2026.
- Individual participant dataSharing planned: No
Related trials for Systemic Lupus Erythematosus (SLE)
RecruitingPhase 1
A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body
Rheumatoid Arthritis, Systemic Lupus Erythematosus
RecruitingObservational study
Deciphering the Genetic Architecture of Autoimmune Diseases
Autoimmune Diseases
RecruitingPhase 1
To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
Lupus Erythematosus, Systemic
RecruitingPhase 3
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
Not yet recruiting
MYTP01 for Immune-Mediated Diseases
IgA Nephropathy, Kidney Transplant Recipients
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Early Phase 1 study testing CAR-T Therapy in people with Systemic Lupus Erythematosus (SLE), run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 18 inclusion and 23 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 14 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Qiubai Li (Professor 85726808 Ext.027, qiubaili@hust.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
severity of dose limiting toxicity (DLT) (time frame: Within 28 days after infusion). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jan 2026.